AEONNN How It Works Pillars Membership FAQ Journal AEONNNian Access Request Early Access

Liposomal and Enhanced Delivery: When It Matters

Delivery enhancement matters decisively for a few compounds and not at all for most, and the distinction is whether absorption was the limiting factor.

7 min read

The Short Answer

Enhanced delivery is applied indiscriminately across the supplement market and matters for a small number of compounds. The question that separates them is simple: was absorption the limiting factor? For curcumin, whose plain form is very poorly absorbed, enhancement is the difference between a trial result and nothing. For vitamin C, which is already well absorbed at ordinary doses, liposomal formulation is solving a problem that does not exist.

The Enhancement Technologies

Liposomal. The compound is encapsulated in phospholipid vesicles, proposed to improve absorption and to protect the compound through the gut. Genuinely useful for some compounds, and the term is applied loosely, with many products described as liposomal being simple phospholipid mixtures rather than characterised liposomes.

Phytosome and phospholipid complex. The compound is complexed with phospholipids, with reasonable pharmacokinetic data for several botanical compounds including curcumin and silymarin.

Micellar and nanoemulsion. The compound is dispersed in surfactant micelles, improving solubility for lipophilic compounds. Well-characterised improvements for curcumin and some carotenoids.

Piperine co-administration. Black pepper extract inhibits glucuronidation and P-glycoprotein, raising plasma levels of several compounds including curcumin. Effective, and it also raises levels of some medications, which is an interaction risk rather than a neutral addition.

Cyclodextrin complexation and solid dispersions, improving solubility.

Sublingual and buccal, bypassing first-pass metabolism for some compounds and largely ineffective for large molecules.

The question for each is not whether the technology works in principle but whether the specific compound needed it.

Where It Genuinely Matters

CompoundWhy enhancement matters
CurcuminPlain form very poorly absorbed and rapidly conjugated; trial results come from enhanced formulations
Coenzyme Q10Poorly water-soluble; solubilised and ubiquinol forms absorb better
Fat-soluble vitamins in malabsorptionWhere fat absorption is impaired, water-miscible forms have a clinical rationale
Resveratrol and quercetinExtensive conjugation; enhancement raises levels, though whether it reaches useful concentrations is unresolved
BerberinePoor and variable bioavailability; enhanced forms exist and the trial base used plain berberine
SilymarinPhospholipid complexes have established pharmacokinetic improvements
Astaxanthin and carotenoidsLipophilic; formulation and dietary fat both matter

Curcumin is the clearest case and worth stating plainly: the osteoarthritis and inflammatory marker trials used bioavailability-enhanced formulations, so a plain curcumin or turmeric powder product is not the studied intervention. Here the enhancement is not a premium feature, it is the product.

The resveratrol row illustrates the limit of the argument. Enhancement raises plasma levels, and whether it raises them to the concentrations used in the cell-culture work that motivated the compound is a separate and unresolved question. Better absorption of something that needs an unreachable concentration may still not be enough.

Where It Does Not Matter

Vitamin C. Well absorbed at ordinary doses through active transport, with absorption falling at high doses because the transporters saturate. Liposomal formulations may raise plasma levels beyond that ceiling, and whether higher plasma vitamin C produces any benefit is unestablished, since the outcome trials of high-dose vitamin C were unimpressive.

Creatine monohydrate. Nearly completely absorbed. Every alternative form, including those marketed on absorption, has failed to demonstrate superiority.

Most B vitamins, well absorbed in standard forms.

Magnesium, where the form affects tolerance and absorption, and the enhancement premium is unnecessary since glycinate and citrate are inexpensive.

Glutathione, oral. Extensively marketed in liposomal form. Oral glutathione is broken down and the evidence that any oral form meaningfully raises tissue glutathione is limited; N-acetylcysteine as a precursor has a better rationale.

NAD+ itself. No delivery technology addresses the fundamental problem, which is that the molecule does not cross cell membranes intact. It is degraded to precursors regardless of how it is packaged.

Collagen peptides, already hydrolysed to absorbable size.

The pattern: where a compound is already well absorbed, enhancement adds cost and not effect.

How to Evaluate an Enhancement Claim

Ask what the plain form's bioavailability is. If it is good, enhancement is unnecessary. This single question resolves most cases.

Ask whether the trials used the enhanced form. For curcumin they did, which makes enhancement necessary. For most compounds they did not, which means the enhanced version is untested rather than better.

Ask whether higher plasma levels have been shown to help. Raising levels is a pharmacokinetic result, not an outcome. High-dose vitamin C is the cautionary example: liposomal delivery may raise levels and the outcome trials at high doses were unimpressive regardless.

Ask whether it is characterised. Liposomal is used loosely, and many products described that way are phospholipid mixtures without documented vesicle formation or stability data.

Ask about the cost multiple. Enhanced forms frequently cost several times the plain form, which is justified for curcumin and rarely elsewhere.

Check for interaction consequences. Piperine raises plasma levels of several medications by the same mechanism it uses on curcumin, which makes it an interaction risk rather than a neutral enhancer.

Consider the free alternative. Taking a fat-soluble compound with a fat-containing meal improves absorption substantially at no cost, and it is the most reliable enhancement available.

The Practical Position

Pay for enhancement where the trials used it: curcumin above all, and it is not optional there. Solubilised or ubiquinol CoQ10 is reasonable.

Do not pay for it on vitamin C, creatine, B vitamins, magnesium, collagen peptides, or oral glutathione.

Use the free enhancements first. Fat-soluble compounds with a fat-containing meal. Iron with vitamin C and away from calcium, tea and coffee. Alternate-day iron dosing, which achieves higher fractional absorption than daily. These are more reliable than most paid enhancements.

Be sceptical of liposomal as a general premium, particularly where the term is unaccompanied by characterisation data.

Remember that better absorption is not better outcome. A compound that needs an unreachable concentration may remain out of reach even with enhancement, which is the position of most of the polyphenol category.

And remember what enhancement cannot fix: a compound with no human outcome evidence remains unevidenced no matter how well it is absorbed. Delivery addresses one of the seven filters between a paper and a recommendation, and passing it does not pass the others.

The AEONNN Perspective

Delivery enhancement is a Pharmacokinetics layer question, and it resolves with a single test: was absorption the limiting factor? For curcumin it was, decisively, since plain curcumin is very poorly absorbed and every positive trial used an enhanced formulation. There enhancement is not a premium feature but the product itself.

For most compounds it was not. Vitamin C is well absorbed at ordinary doses through saturable transport, creatine monohydrate is nearly completely absorbed, and B vitamins and magnesium have inexpensive well-absorbed forms. Enhancement there adds cost without effect, and the platform does not recommend paying for it.

Two limits the platform states explicitly. Better absorption is not a better outcome: raising plasma levels of a compound whose useful concentration is unreachable, or whose outcome trials were unimpressive at high doses, does not produce a benefit. And enhancement addresses only one of the filters between a paper and a recommendation, so a compound with no human outcome evidence remains unevidenced however well it is delivered. The free enhancements, taking fat-soluble compounds with fat and alternate-day iron dosing, outperform most paid ones.

Pillar Matrix mapping

Longevity and Biological Age

Database Matrix layers

  • Pharmacokinetics Layer (HMDB, PubChem)
  • Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
  • Quality / Formulation Layer (ConsumerLab, Labdoor)
  • Meta / Consensus Layer (JAMA, BMJ, specialty society positions)

Frequently Asked

Does liposomal delivery work?

For some compounds, decisively. The question is whether absorption was the limiting factor, and for most well-absorbed compounds it was not, so enhancement adds cost without effect.

Which compounds genuinely need enhancement?

Curcumin above all, since plain curcumin is very poorly absorbed and every positive trial used an enhanced formulation. Coenzyme Q10 benefits from solubilised or ubiquinol forms.

Is liposomal vitamin C worth it?

Vitamin C is well absorbed at ordinary doses, absorption saturates at high doses, and whether higher plasma levels produce any benefit is unestablished since high-dose outcome trials were unimpressive.

Does enhancement help NAD+ supplements?

No delivery technology addresses the fundamental issue, which is that NAD+ does not cross cell membranes intact and is degraded to precursors regardless of packaging.

Is piperine a neutral addition?

No. It raises plasma levels of several medications by the same glucuronidation and P-glycoprotein mechanism it uses on curcumin, which makes it an interaction risk.

What is the cheapest enhancement?

Taking fat-soluble compounds with a fat-containing meal, iron with vitamin C away from calcium and tea, and alternate-day iron dosing, which achieves higher fractional absorption than daily.

Does better absorption mean a better outcome?

No. Raising levels is a pharmacokinetic result rather than an outcome, and a compound with no human outcome evidence remains unevidenced however well it is absorbed.

Evidence and review

Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.

Continue Reading

Membership

Reading about longevity and Biological Age is not the same as knowing where you stand.

AEONNN organizes an article like this one against your own profile. Origin works through Discovered Mode, building your Pillar Matrix from the context you provide. Evolution adds Synched Mode, so supported wearable, Apple Health and laboratory data inform the same reasoning.

AEONNN turns knowledge like this into a protocol that is yours.

Private Early Access opens in August. Public launch follows in September.

By requesting access, you agree to receive AEONNN launch and membership communications. You may unsubscribe at any time. Privacy Policy · Consumer Health Data Privacy Notice

Back to the Journal →